Spyre Therapeutics, Inc. (SYRE)

Market Cap	1.40B
Revenue (ttm)	n/a
Net Income (ttm)	-214.90M
Shares Out	58.71M
EPS (ttm)	-5.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,208,163
Open	22.90
Previous Close	23.13
Day's Range	22.62 - 24.88
52-Week Range	16.90 - 47.97
Beta	2.84
Analysts	Strong Buy
Price Target	51.50 (+115.84%)
Earnings Date	Nov 7, 2024

About SYRE

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-α4β7)...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2016
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: SYRE
• Website: https://www.spyre.com

Financial Performance

In 2023, Spyre Therapeutics's revenue was $886,000, a decrease of -61.96% compared to the previous year's $2.33 million. Losses were -$338.79 million, 304.2% more than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price forecast is $51.5, which is an increase of 115.84% from the latest price.

Price Target

$51.5

(115.84% upside)

Analyst Consensus: Strong Buy